12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

SMT C1100 regulatory update

FDA granted Orphan Drug designation for Summit's SMT C1100 to treat Duchenne muscular dystrophy (DMD). The small molecule utrophin up-regulator has Orphan Drug designation from EMA for...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >